新型实时模型预测危重患者12小时内急性肾损伤
该前瞻性队列研究纳入680例训练集和249例验证集患者,最终417例和164例纳入分析,构建了基于三种尿液生物标志物(α1MG、L-FABP、IGFBP7)的U-AKIpredTM模型,用于预测危重患者12小时内急性肾损伤(AKI)。训练集AUC为0.802(95%CI: 0.771-0.833, P<.001),验证集AUC为0.844(95%CI: 0.792-0.896, P<.001),模型预测性能优于其他12种肾损伤标志物及NephroCheck®。
要点
- U-AKIpredTM基于α1MG、L-FABP和IGFBP7三种尿液标志物预测12h内AKI。
- 训练集AUC 0.802,验证集AUC 0.844,预测性能良好。
- 模型净获益和风险重分类优于12种单一标志物及NephroCheck®。
核心结论
- U-AKIpredTM是预测危重患者12小时内AKI的优秀模型,有助于识别高风险患者。
研究设计与样本
- 前瞻性队列研究,训练集680例、验证集249例,经纳入排除后分别纳入417例和164例,AKI按KDIGO标准诊断。
主要发现
- 12种尿液肾损伤标志物对12小时内AKI有良好预测性能。
- U-AKIpredTM联合α1MG、L-FABP和IGFBP7三种标志物,预测性能优于其他12种标志物。
- 训练集AUC为0.802(95%CI: 0.771-0.833, P<.001),验证集AUC为0.844(95%CI: 0.792-0.896, P<.001)。
- 决策曲线分析和临床影响曲线显示U-AKIpredTM净获益高于12种标志物。
- U-AKIpredTM预测AKI和严重AKI的效率优于NephroCheck®。
关键数值与推荐
- AKI诊断采用KDIGO标准。
- U-AKIpredTM训练集AUC 0.802(95%CI: 0.771-0.833, P<.001),验证集AUC 0.844(95%CI: 0.792-0.896, P<.001)。
临床怎么用
- 可利用U-AKIpredTM动态列线图(网页计算器)实时评估危重患者12小时内AKI风险,辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A major challenge in the prevention and early treatment of acute kidney injury (AKI) is the lack of high-performance predictors in critically ill patients. Therefore, we innovatively constructed U-AKIpredTM for predicting AKI in critically ill patients within 12 h of panel measurement. METHODS: The prospective cohort study included 680 patients in the training set and 249 patients in the validation set. After performing inclusion and exclusion criteria, 417 patients were enrolled in the training set and 164 patients were enrolled in the validation set. AKI was diagnosed by Kidney Disease: Improving Global Outcomes (KDIGO) criteria. RESULTS: Twelve urinary kidney injury biomarkers (mALB, IgG, TRF, α1MG, NAG, NGAL, KIM-1, L-FABP, TIMP2, IGFBP7, CAF22, and IL-18) exhibited good predictive performance for AKI within 12 h in critically ill patients. U-AKIpredTM, combined with three crucial biomarkers (α1MG, L-FABP, and IGFBP7) by multivariate logistic regression analysis, exhibited better predictive performance for AKI in critically ill patients within 12 h than the other 12 kidney injury biomarkers. The area under the curve (AUC) of the U-AKIpredTM, as a predictor of AKI within 12 h, was 0.802 (95% CI: 0.771-0.833, P < .001) in the training set and 0.844 (95% CI: 0.792-0.896, P < .001) in the validation cohort. A nomogram based on the results of the training and validation sets of U-AKIpredTM was developed that showed optimal predictive performance for AKI. The fitting effect and prediction accuracy of U-AKIpredTM was evaluated by multiple statistical indicators. To provide a more flexible predictive tool, the dynamic nomogram (https://www.xsmartanalysis.com/model/U-AKIpredTM) was constructed using a web calculator. Decision curve analysis and a clinical impact curve were used to reveal that U-AKIpredTM with the three crucial biomarkers had a higher net benefit than these 12 kidney injury biomarkers, respectively. The net reclassification index and integrated discrimination index were used to improve the significant risk reclassification of AKI compared with the 12 kidney injury biomarkers. The predictive efficiency of U-AKIpredTM was better than the NephroCheck® when testing for AKI and severe AKI. CONCLUSION: U-AKIpredTM is an excellent predictive model of AKI in critically ill patients within 12 h and would assist clinicians in identifying those at high risk of AKI.
引用
- Sun T, Yue X, Chen X, et al. A novel real-time model for predicting acute kidney injury in critically ill patients within 12 hours. Nephrol Dial Transplant. 2025. PMID: 39020258. doi:10.1093/ndt/gfae168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。